The Bio Report Podcast: Using AI Created Digital Twins to Accelerate Clinical Trials

One of the challenges of conducting clinical trials is finding enough patient to include in a control arm of a study. This can slow the pace of drug development and increase its costs. Unlearn.AI is seeking to change that by using its artificial intelligence platform to create digital twins of trial participants that can serve as control arms in studies. We spoke to Charles Fisher, founder and CEO of Unlearn, about the concept of digital twins, the potential to accelerate clinical trials with their use, and why the company is focusing on the area of complex neurologic diseases.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Why can’t we agree on how to define digital twins in healthcare?

White Papers

Summary of the EMA September 2022 Qualification Opinion for PROCOVA™

Press

Charles Fisher, Unlearn.AI: “now is the time to adopt AI-based solutions”

The potential for AI implementation in healthcare can barely be measured, as it can already do what humans do, just countless times better and more efficiently.
The European Medicines Agency has qualified Unlearn’s AI-powered method for running smaller, faster clinical trials.
Digital twins seem to be everywhere in healthcare now, but no one agrees on a single definition for them.